Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Hematopoietic Stem Cell Transplantation/mortality"'
Autor:
Urs Schanz, Claire Seydoux, Nathan Cantoni, Patrick Simon, Stavroula Masouridi Levrat, Sabine Gerull, Joerg Halter, Michael Medinger, Yves Chalandon, Gayathri Nair, Dominik Heim, Marc Ansari, Jakob Passweg
Publikováno v:
Annals of Hematology
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46778682dca6af300f13a48b5a897ccf
http://europepmc.org/articles/PMC7782401
http://europepmc.org/articles/PMC7782401
Autor:
Martin Goerner, Markus Munder, Martin Hoffmann, Katja Weisel, Peter Brossart, Elias K. Mai, Anja Seckinger, Hans Salwender, Bernhard Rabold, Dirk Hose, Thomas Hielscher, Igor Wolfgang Blau, Uta Bertsch, Steffen Luntz, Ahmet H. Elmaagacli, Stefanie Huhn, Nicola Giesen, Hartmut Goldschmidt, Jens Hillengass, Marc S. Raab, Christina Kunz, Christof Scheid, Anna Jauch, Maximilian Merz, Diana Tichy, Barbara Hügle-Dörr, Hans-Walter Lindemann, Mathias Hänel, Helga Bernhard, Jan Dürig, Stephan Fuhrmann
Publikováno v:
Leukemia. 34:1853-1865
The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d3744d392b8b60be666bc6b8b4d70d
https://doi.org/10.1038/s41375-020-0724-1
https://doi.org/10.1038/s41375-020-0724-1
Autor:
Sylvain Chantepie, Cécile Fourrage, Françoise Huguet, Patrice Chevallier, Elizabeth Macintyre, Hervé Dombret, Nicolas Boissel, Emmanuelle Tavernier, Véronique Lhéritier, Stéphane Leprêtre, Loïc Passini, Vahid Asnafi, Sébastien Maury, Martine Escoffre, Carlos Graux, Ludovic Lhermitte, Emmanuel Raffoux, Patrick Villarese, Norbert Ifrah, Yves Chalandon, Thibaut Leguay, Thorsten Braun, Xavier Thomas, Mathilde Hunault, Rathana Kim, Florian Thonier, Aurore Touzart
Publikováno v:
Leukemia
Leukemia, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Springer Nature, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Vol. 34, No 7 (2020) pp. 1730-1740
Leukemia, Vol. 34, no. 7, p. 1730-1740 (2020)
Leukemia, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Springer Nature, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2020, Epub ahead of print. ⟨10.1038/s41375-019-0685-4⟩
Leukemia, Vol. 34, No 7 (2020) pp. 1730-1740
Leukemia, Vol. 34, no. 7, p. 1730-1740 (2020)
International audience; The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive study of 200 adult patients with TALL included in the GRAALL2003/2005
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2432887b9d2caa6fd17a1247a9f312d6
https://www.hal.inserm.fr/inserm-02551756/document
https://www.hal.inserm.fr/inserm-02551756/document
Autor:
Rasmus Heje Thomsen, Jette Sønderskov Gørløv, Søren Ramme Nielsen, Charlotte Madsen, Susanne Oksbjerg Dalton, Kristina Fruerlund Nielsen, Peter de Nully Brown, Maja Halgren Olsen, Bente Arboe, Anne Katrine Duun-Henriksen
Publikováno v:
Arboe, B, Halgren Olsen, M, Duun-Henriksen, A K, Gørløv, J S, Nielsen, K F, Thomsen, R H, Madsen, C, Ramme Nielsen, S, Dalton, S O & Brown, P D N 2018, ' Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation ', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162 . https://doi.org/10.1080/10428194.2017.1369061
Arboe, B, Halgren Olsen, M, Duun-Henriksen, A K, Gørløv, J S, Nielsen, K F, Thomsen, R H, Madsen, C, Nielsen, S R, Dalton, S O & Brown, P D N 2018, ' Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation ', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162 . https://doi.org/10.1080/10428194.2017.1369061
Arboe, B, Halgren Olsen, M, Duun-Henriksen, A K, Gørløv, J S, Nielsen, K F, Thomsen, R H, Madsen, C, Nielsen, S R, Dalton, S O & Brown, P D N 2018, ' Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation ', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162 . https://doi.org/10.1080/10428194.2017.1369061
In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing AS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1740139ca7428f6006413c145c81abc
https://portal.findresearcher.sdu.dk/da/publications/1af97bf7-5eb6-4557-a706-f2b00777ae55
https://portal.findresearcher.sdu.dk/da/publications/1af97bf7-5eb6-4557-a706-f2b00777ae55
Autor:
André Tichelli, Helen Baldomero, Giorgio Dini, Jane F. Apperley, Jakob Passweg, Vanderson Rocha, Anna Sureda, Marrow Transplantation, Martin Stern, Theo de Witte, Alois Gratwohl, Dietger Niederwieser, Ronald Brand
Publikováno v:
Cancer, Vol. 115, No 20 (2009) pp. 4715-4726
CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cancer, 115, 4715-26
Cancer, 115, 20, pp. 4715-26
CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cancer, 115, 4715-26
Cancer, 115, 20, pp. 4715-26
Contains fulltext : 81638.pdf (Publisher’s version ) (Closed access) BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established for chronic myeloid leukemia, could be used to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ea262b738f5026a572dc34f4dfba75
https://doi.org/10.1002/cncr.24531
https://doi.org/10.1002/cncr.24531
Autor:
Passweg, J, Baldomero, H, Stern, M, Bargetzi, M, Ghielmini, M, Leibundgut, K, Duchosal, M, Hess, U, Seger, R, Buhrfeind, E, Schanz, U, Gratwohl, A
Publikováno v:
Schweizerische medizinische Wochenschrift, Vol. 140, No 23-24 (2010) pp. 326-334
Swiss medical weekly, vol. 140, no. 23-24, pp. 326-334
Swiss medical weekly, vol. 140, no. 23-24, pp. 326-334
QUESTIONS UNDER STUDY / PRINCIPLES: Interest groups advocate centre-specific outcome data as a useful tool for patients in choosing a hospital for their treatment and for decision-making by politicians and the insurance industry. Haematopoietic stem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a370a4157ee6b3e06f32ded2ae4360f
https://www.zora.uzh.ch/id/eprint/41621/
https://www.zora.uzh.ch/id/eprint/41621/
Autor:
Myriam Labopin, Vanderson Rocha, Depei Wu, Giuseppe Irrera, Arnon Nagler, Aida Botelho Sousa, Avichai Shimoni, Mohamad Mohty, Antonio P. Torres Gomez, Miguel A. Sanz, Raanan Berger, William Arcese, Norbert Claude Gorin, Jose E. Guimaraes, Simona Lapusan, Norbert Vey, Felicetto Ferrara, Angelo Michele Carella
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Haematologica
Haematologica, 2014, 99 (8), pp.1380-1386. ⟨10.3324/haematol.2014.105197⟩
Haematologica, Ferrata Storti Foundation, 2014, 99 (8), pp.1380-1386. ⟨10.3324/haematol.2014.105197⟩
HAEMATOLOGICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Haematologica
Haematologica, 2014, 99 (8), pp.1380-1386. ⟨10.3324/haematol.2014.105197⟩
Haematologica, Ferrata Storti Foundation, 2014, 99 (8), pp.1380-1386. ⟨10.3324/haematol.2014.105197⟩
HAEMATOLOGICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26aee93e2d235d56d14620813107a5b
Autor:
Philippe Schneider, Tayfun Güngör, Jakob Passweg, Yves Chalandon, Urs Schanz, Jean-Marie Tiercy, Alois Gratwohl, Reinhard Seger, Dominik Heim, Grazia Nicoloso, Rudolf Schwabe
Publikováno v:
Bone Marrow Transplantation, Vol. 40, No 6 (2007) pp. 515-22
Identification of an unrelated HLA allele-matched hematopoietic stem cell (HSC) donor is a costly and time-consuming procedure. To improve search logistics, we have limited the search period to 6 months and have introduced a probability estimate of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b074e0f4b3f90ce40cece3cb7c2d82a1
https://archive-ouverte.unige.ch/unige:26018
https://archive-ouverte.unige.ch/unige:26018
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.